Cullinan Oncology Inc. (CGEM)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
10.01
-1.03 (-9.33%)
At close: Jan 14, 2025, 3:59 PM
10.05
0.39%
Pre-market Jan 15, 2025, 08:30 AM EST
Ratios (Annual)
Discover comprehensive ratio statement breakdowns that reveal insights into revenue, expenses, and beyond.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
PE Ratio | -2.76 | 4.28 | -10.51 | -25.6 | -64.96 | -24.14 |
PS Ratio | n/a | n/a | 36.08 | n/a | n/a | n/a |
PB Ratio | 0.93 | 0.89 | 1.62 | -16.76 | -31.92 | -16.58 |
P/FCF Ratio | -3.15 | -3.73 | -15.52 | -43.7 | -62.23 | -24.8 |
P/OCF Ratio | -3.15 | -3.76 | -15.74 | -43.72 | -62.28 | -25.28 |
OCF/S Ratio | n/a | n/a | -2.29 | n/a | n/a | n/a |
Debt / Equity Ratio | 0.01 | 0.01 | n/a | n/a | n/a | n/a |
Quick Ratio | 17.07 | 21.09 | 25.25 | 14.82 | 39.67 | 25.85 |
Current Ratio | 17.07 | 21.09 | 25.25 | 14.82 | 39.67 | 25.85 |
Asset Turnover | n/a | n/a | 0.04 | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity (ROE) | -0.34 | 0.21 | -0.15 | 0.65 | 0.49 | 0.69 |
Return on Assets (ROA) | -0.32 | 0.20 | -0.15 | -0.24 | -0.2 | -0.41 |
Return on Capital (ROIC) | -0.42 | 0.27 | -0.16 | -0.3 | -0.23 | -0.44 |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | 99.72% | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | -343.35% | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | -356.25% | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | -358.73% | n/a | n/a | n/a |
FCF Margin | n/a | n/a | -232.39% | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | -358.45% | n/a | n/a | n/a |